Skip to main content

Table 1 Patients characteristics

From: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Parameter Median [range] or N (%)
Total N = 100
Age (years) 49 years [16–74]
Female 57 (57)
Transcript type
 b3a2 50 (50)
 b2a2 30 (30)
 b2a2 + b3a2 17 (17)
 b2a3 1 (1)
Sokal score
 Low risk < 0.8 35 (35)
 Intermediate risk 0.8–1.2 21 (21)
 High risk > 1.2 4 (4)
 Not available 40 (40)
Treatment  
 Previously treated with interferon 32 (32)
 Frontline imatinib 43 (43)
 Frontline dasatinib 13 (13)
 Frontline nilotinib 9 (9)
 Frontline ponatinib 2 (2)
 Frontline bosutinib 1 (1)
Number of TKI lines
 1 line 68 (68)
 ≥ 2 lines 32 (32)
TKI at time of discontinuation
 Imatinib 47 (47)
 Dasatinib 35 (35)
 Nilotinib 14 (14)
 Bosutinib 2 (2)
 Ponatinib 2 (2)
Response
 BCR-ABL/ABL at 3 months
  < 10% (IS) 53 (95)
  ≥ 10% (IS) 3 (5)
 Duration (months) from start of TKI to CCyR 4 [2–78]
 Duration (months) from start of TKI to MMR 7 [1–91]
 Duration (months) from start of TKI to MR4.5 17 [2–146]
At discontinuation
Duration (months) from diagnosis to discontinuation 119 [11–403]
Duration (months) of last TKI before discontinuation 82 [1–198]
 Imatinib 121 [11–198]
 Dasatinib 64 [5–163]
 Nilotinib 71 [1–119]
 Bosutinib 47 [38–126]
 Ponatinib 15 [15–15]
Duration (months) of MR4.5 before discontinuation 75 [1–178]
 < 2 years 11 (11)
 2 to 4 years 15 (15)
 4 to 6 years 20 (20)
 6 to 8 years 17 (17)
 8 to 10 years 20 (20)
  ≥10 years 17 (17)
Reason for TKI Discontinuation
 Adverse events 53 (53)
  Second cancer 2 (4)
 Elective 47 (47)
  Sustained MR4.5 38 (84)
  Pregnancy 6 (13)
  Financial reasons 3 (7)
Outcome after TKI discontinuation
 Follow-up (months) after TKI discontinuation 30 [5–112]
 Loss of MR4.5 35 (35)
 Loss of MMR 17 (17)
Retreatment 30 (30)
 MMR after retreatment 29 (97)
 MR4.5 after retreatment 28 (93)
 Lost to follow-up after retreatment 1 (3)
Status on last follow-up
 CCyR 2 (2)
 MMR 5 (5)
 MR4.5 85 (85)
 Death 8 (8)a
  1. CCyR complete cytogenetic response, IS international score, MMR major molecular response, MR4.5 molecular response of 4.5-log reduction from baseline, TKI tyrosine kinase inhibitor
  2. aAll patients died while in MR4.5